Apogee Therapeutics has announced promising midstage clinical trial results for APG777, its experimental long-acting antibody therapy targeting atopic dermatitis. The trial demonstrated that APG777 effectively reduced signs and symptoms of eczema, achieving efficacy comparable to market leaders Dupixent by Sanofi and Regeneron's and Eli Lilly's Ebglyss. Notably, APG777 is designed for quarterly or biannual injections, offering a more convenient dosing schedule than the current monthly or bi-monthly regimens. These findings position APG777 as a competitive potential alternative in a crowded therapeutic space pending further clinical validation.